Woodline Partners LP Bio Atla, Inc. Transaction History

Woodline Partners LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.88 - $3.46 $250,442 - $460,920	133,214 New	133,214 $458,000
Q4 2022 Feb 14, 2023	BUY	$6.29 - $11.01 $284,421 - $497,850	45,218 New	45,218 $373,000
Q1 2022 May 16, 2022	SELL	$4.38 - $18.78 $1.95 Million - $8.38 Million	-446,141 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$19.0 - $30.95 $5.61 Million - $9.14 Million	295,446 Added 196.06%	446,141 $8.76 Million
Q3 2021 Nov 15, 2021	BUY	$29.44 - $43.74 $4.44 Million - $6.59 Million	150,695 New	150,695 $4.44 Million

17.3M

500

33.5K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $62.4M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.